• BioGenex Molecular Pathology system aids in early polyp detection and prevention of Colorectal Cancer

    Colon Cancer_Nature MedicineColorectal cancer (CRC) is the second leading cause of cancer death in the United States with an estimated 50,000 deaths in 2016. Colonoscopy is the leading CRC screening strategy, and there is strong evidence that the removal of polyps detected by colonoscopy can prevent the development of CRC. However, colonoscopy screenings only provide partial protection due to the limitations of current polyp detection techniques and human factors such as the skill of the endoscopist.  These contribute to diagnostic miss rates of up to 25%. In a new study published in Nature Medicine, an international team of researchers used the BioGenex automated molecular pathology staining system to  develop a fluorescence colonoscopy technique that can accurately identify a polyp biomarker (i.e. c-Met) and thus improve polyp detection during colonoscopy screenings.

    c-Met, also known as hepatocyte growth factor receptor (HGFR), is a single pass tyrosine kinase receptor essential for embryonic development, organogenesis and wound healing. Normally, only stem cells and progenitor cells express c-Met, which allows these cells to grow invasively in order to generate new tissues in an embryo or regenerate damaged tissues in an adult.  Cancer stem cells are thought to hijack the ability of normal stem cells to express c-Met. The overexpression of c-Met has been shown to occur as an early event in the colorectal adenoma-carcinoma sequence, making it a suitable biomarker for colorectal neoplasia. In the new study, GE-137, a fluorescent probe with high affinity to c-Met was generated, and its biodistribution, pharmacokinetics and binding specificity were assessed in a xenograft mouse model using the human CRC cell line HT29. These preclinical studies showed that GE-137 accumulates specifically in human colorectal tumors and provides sufficient contrast to enable detection of c-Met-rich lesions. GE-137 was shown to be safe and well tolerated in humans. Fluorescence colonoscopy in patients receiving intravenous GE-137 detected all neoplastic polyps that were visible with white light, as well as an additional nine polyps that were missed by white light detection. To confirm that these polyps were indeed adenomas or hyperplastic polyps and expressed c-Met, all biopsies were evaluated by histology and immunohistochemistry (IHC) assays. The BioGenex EZ Retriever microwave was used for antigen retrieval, and the BioGenex i6000 automated staining system was used for staining with the c-Met specific antibody. Overall, fluorescence findings in vivo matched the histological findings. Whereas c-Met is expressed in normal colon tissue and is evenly expressed along the crypt axis on the epithelial cell membrane, it is significantly more highly expressed in both hyperplastic and adenomatous polyps, which corresponds to the binding of the fluorescent probe to the c-Met in vivo. This first-in-human pilot study shows that molecular imaging using an intravenous fluorescent agent specific for c-Met is feasible and safe, and that it may enable the detection of polyps missed by other techniques.

    For more details click here

    About Us:

    BioGenex designs, develops, and commercializes advanced fully-automated molecular pathology systems for cancer diagnosis, prognosis, personalized medicine, and life science research. The recent introduction of our eFISHency integrated workflow solution for FISH laboratories and miRNA system for characterization of CUP and for undifferentiated tumors is a game changer that has no rival in the industry. Our fully-automated molecular pathology workstations are the most advanced system globally. Our customer focused approach, with premier after sales support and excellent technical service, provides the best in class customer care. Our spirit of innovation drives us to deliver cutting edge technology, years ahead of our competition, and the finest systems for life Science research and diagnostics.

    Continue reading
  • BioGenex Scientists Develop Panel of miRNAs: Promising Tool for Prognostication of Early Stage Triple Negative Breast Cancer

    By Marcos Arribas-Layton, PhD. June 7, 2016

    Like many cancers, breast cancers are highly diverse with a range of distinct clinical outcomes. Breast cancers dependent on hormone signaling (ER/PR) or on EGF-receptor (HER2/neu) typically have the most positive prognosis. Tumors lacking these receptors expression, referred to as Triple Negative Breast Cancer (TNBC), currently have no targeted therapies available. Five-year survival rates plummet from nearly 99% for localized tumors to 24% in late stage cancers and therefore correct identification of breast cancer subtypes at early stage is critical for treatment effectiveness.

    Researchers speculate that miRNAs are potential biomarker candidates for early detection and prognosis prediction, because dysregulation of miRNA has been widely reported in cancers1. Recent studies have tested miRNAs as predictive biomarkers for determining TNBC patient’s prognosis. A four-miRNA signature (miR-16, miR-125b, miR-155 and miR374a) correlated with shorter overall patient survival1. A different panel of four miRNAs (miR-27a, -30e, -155, and -493) could separate TNBC into two distinct subgroups, high risk “core basal” tumors (basal CK5/6-and/or EGFR-positive) compared to lower risk “5 negative” tumors (negative for all five markers; ER, PR, HER2, CK5/6 and EGFR) 1-2. These results may help doctors decide which TNBC patient may require more aggressive treatment.

    miRNA---TNBC-Social-Medial-images

     

    In situ hybridization (ISH) assay is a powerful tool to determine altered miRNA expression in tumors, and to assess the contribution of reactive stroma and immune response to tumor progression. High levels of miR-21 expression in the stromal compartment in a cohort of 105 early-stage TNBC cases correlated with shorter recurrence-free survival3.

    BioGenex is an industry leader in miRNA-ISH. Unlike PCR based techniques, BioGenex ISH system has the ability to generate robust chromogenic signal while preserving the spatial context of the tissue sample thus allowing precise tumor characterization. BioGenex offers over 200 miRNA probes together with ISH detection systems, and automation-based platforms, which allow high throughput and accurate detection of miRNAs in tissue samples. BioGenex’s unique miRNA probe technology enables detection of single nucleotide mismatch thus allowing high sensitivity and specificity with a clean intense staining.

    Please email customer.service@biogenex.com for additional information and to submit an order.

    About BioGenex

    BioGenex designs, develops, and commercializes advanced fully-automated molecular pathology systems for cancer diagnosis, prognosis, personalized medicine, and life science research. The recent introduction of our eFISHency integrated workflow solution for FISH laboratories and miRNA system for characterization of CUP and for undifferentiated tumors is a game changer that has no rival in the industry. Our fully-automated molecular pathology workstations are the most advanced system globally. Our spirit of innovation drives us to deliver cutting edge technology, years ahead of our competition, and the finest systems for life Science research and diagnostics.

     

    1Critical analysis of the potential for microRNA biomarkers in breast cancer management. Graveel CR, Calderone HM, Westerhuis JJ, Winn ME, Sempere LF, Breast Cancer: Targets and Therapy, 2015(7) 59-79 and references therein

    2The Oncogenic microRNA-27a Targets Genes That Regulate Specificity Protein Transcription Factors and the G2-M Checkpoint in MDA-MB-231 Breast Cancer Cells.Mertens-Talcott SU, Chintharlapalli S, Li X, and Safe S, Cancer Research, 2007(67) 11001-11

    3Circulating MicroRNA-21 Is Involved in Lymph Node Metastasis in Cervical Cancer by Targeting RASA1. Zhang L, Zhan X, Yan D, Wang Z, Int J Gynecol Cancer, 2016 Apr (in press)

    Continue reading
  • BioGenex FISH automation platform helps identify Non-Hodgkin’s Lymphoma patients for MCL-1/BCL2 combination therapy.

    May 18, 2016

    Biogenex Lymphoma

    In a new study, published in Nature’s Blood Cancer Journal, researchers using the Xmatrx FISH automation system identified MCL-1 as a target for therapy in resistant Non-Hodgkin’s lymphoma (NHL). NHL is a type of cancer that starts in the lymphatic system, a part of the immune system, and can spread to various organs including bone marrow, liver and brain. NHL is one of the most common cancers in the United States, accounting for about 4% of all cancers. In 2016 an estimated 73,000 people will be diagnosed with NHL and 20,000 people will die from this cancer in the US. On average, the survival rate for people with NHL (stages I-IV) over five years is 69% and over ten years drops to 59%. Symptoms include swollen lymph nodes, fever, belly pain, or chest pain while treatments may include chemotherapy, radiation therapy, stem-cell transplant, or medications. Since there is not a standard screening test for non-symptomatic individuals, NHL is often not diagnosed until the later stages, which have less favorable prognosis rates.

    The t(14; 18) chromosomal translocation (an abnormal exchange of genetic material between non-homologous chromosomes) is a biomarker of certain types of NHL, and when present results in a hyperexpression of the B-cell lymphoma protein-2 (BCL-2).  This protein works to inhibit cell death, and when overexpressed is associated with a lower survival rate.  Current drugs that target BCL-2 are now being evaluated in clinical trials; Navitoclax (ABT-263) is a broad spectrum inhibitor that targets BCL-2, BCL-XL and BCL-W, but can lead to BCL-XL-driven thrombocytopenia – a serious life threatening adverse effect. Venetoclax is a specific BCL-2 inhibitor that is better tolerated, but despite improved response rates some cancers remain resistant to both these drugs.

    MCL-1 is a known resistance factor to both drugs, and in the new study scientists at AbbVie sought to identify and block MCL-1 and other resistance factors in order to increase the efficacy of the existing drugs.  They performed Fluorescent In Situ Hybridization (FISH*) using the Biogenex Xmatrx Automated platform to verify the presence of the t(14; 18) chromosomal translocation (and therefore the upregulation of BCL-2). Using selective inhibitors for MCL-1 or BCL-XL in combination with navitoclax and venetoclax they showed that inhibiting MCL-1 increases the sensitivity of cancer cell lines with a high BCL-2 expression to both drugs. These data strongly suggest that co-inhibition of MCL-1 can improve the clinical efficacy of venetoclax. Furthermore, this study also identifies a patient population (BCL2Low) that could potentially benefit from BCL-XL (navitoclax)-driven combination therapy.

    * FISH is a robust technique used for the detection of chromosomal aberrations and is invaluable for both research and diagnosis of solid tumors and hematological malignancies.  In addition to the fully-automated FISH system used by AbbVie (Xmatrx Infinity), BioGenex recently launched the Integrated eFISHiency system which includes: Xmatrx Nano, the world first affordable FISH automation system that fits on a bench-top, 65 highly specific FISH probes and FISH visualization kits for FFPE and Cell sample with validated protocols. BioGenex FISH probes are processed by a unique Repeat Subtraction Technique resulting in advanced specificity and improved signal intensity and their performance is guaranteed.

    For more details please contact our customer service team at 1-(800) 421-4149 ext 1 or Email

    About  BioGenex

    BioGenex designs, develops, and commercializes advanced fully-automated molecular pathology systems for cancer diagnosis, prognosis, personalized medicine, and life science research. The recent introduction of our eFISHency integrated workflow solution for FISH laboratories and miRNA system for characterization of CUP and for undifferentiated tumors is a game changer that has no rival in the industry. Our fully-automated molecular pathology workstations are the most advanced system globally. Our spirit of innovation drives us to deliver cutting edge technology, years ahead of our competition, and the finest systems for life Science research and diagnostics.

    By Stephanie Erhard, May 17, 2016

    Continue reading
  • BioGenex CDX2 helps identify Colon Cancer patients for adjuvant chemotherapy – greatly increasing patient survival.

    May 12, 2016

    Colon cancer is the third most commonly diagnosed cancer and the second leading cause of cancer death in men and women combined in the United States. In 2016 about 140,000 people will be diagnosed and 50,000 will die from this disease. On average, the lifetime risk of developing colon cancer is about 5%, however, this varies widely according to individual risk factors. About 72% of cases arise in the colon and about 28% in the rectum. In recent years, introduction of a new adjuvant chemotherapy for patients with stage III colon cancer, was very successful and significantly increased disease-free survival in these patients. However, there was no improvement in disease-free survival for patients with earlier-stage (stage I and II) disease due to the lack of simple, reliable criteria for the identification of patients who are at high risk for relapse. Now, a groundbreaking study published in the New England Journal of Medicine, demonstrated that CDX2 antibodies from BioGenex (Clone CDX2-88) can be employed in a new prognostic approach and help save lives of stage II Colon Cancer patients.

    The researchers in this study used a new bioinformatics approach to search for a biomarker of colon epithelial differentiation. They screened a 2329 sample pool of gene-expression arrays from primary human colon epithelial tissues and identified the transcription factor CDX2 as their leading candidate. CDX2 protein expression was analyzed in colon-cancer tissue microarrays by immunohistochemistry (IHC), using the BioGenex CDX2 antibody, clone CDX2-88. It was found that the rate of 5-year disease-free survival was only 12% in patients with CDX2-protein-negative colon cancer, compared to 88% in patients with CDX2 protein-positive tumors. These findings were independent of patient’s age, sex, and tumor stage and grade. In addition, stage II patients with CDX2-negative tumor who were treated with adjuvant chemotherapy had a much higher rate of 5-year disease-free survival (91%) as compared to patients who did not receive adjuvant chemotherapy (56% survival). These findings demonstrate that CDX2 expression can identify a subgroup of patients with high-risk stage II colon cancer who benefit from adjuvant chemotherapy.

    For more details click here

    About Us:

    BioGenex designs, develops, and commercializes advanced fully-automated molecular pathology systems for cancer diagnosis, prognosis, personalized medicine, and life science research. The recent introduction of our eFISHency integrated workflow solution for FISH laboratories and miRNA system for characterization of CUP and for undifferentiated tumors is a game changer that has no rival in the industry. Our fully-automated molecular pathology workstations are the most advanced system globally. Our customer focused approach, with premier after sales support and excellent technical service, provides the best in class customer care. Our spirit of innovation drives us to deliver cutting edge technology, years ahead of our competition, and the finest systems for life Science research and diagnostics.

    Continue reading
  • Earth Day 2016 - BioGenex Innovation Protects the Environment and The Planet in Four Ways

    Apr 22, 2016

    Earth_blog-page

     

    BioGenex has a rich history of innovation in the field of Immunohistochemistry (IHC) and In situ Hybridization (ISH) and a strong intellectual portfolio, consisting of several US and foreign-issued patents, which not only revolutionize precision medicine but also support the environment by promoting the use of Green non-toxic reagents and reducing toxic waste and include:

    1. Deparaffinization – The EZ-DeWax deparaffinization solutions is a “one-step” product that simultaneously enables the removal of paraffin and allows rehydration of the tissue with a single reagent. In the past, formalin-fixed, paraffin-embedded tissue sections were traditionally deparaffinized with highly toxic, noxious chemicals (i.e. xylene, equivalents).

    2. Antigen retrieval - BioGenex is the inventor of Antigen Retrieval enabling technology. Antigen Retrieval is an effective way of unmasking antigenic epitopes on the surface of formalin-fixed, paraffin-embedded tissue sections using microwave heating. BioGenex Antigen Retrieval Solutions have unique superheating properties that prevent damage to tissues, allow fast uniform heating and cooling which allow shorter protocols and are non-hazardous, non-flammable, odorless, safe and Eco-Friendly.

    3. Reaction micro-chamber Technology - BioGenex key technology differentiators, including the eXACT temperature control and reaction micro-chamber, not only enable the automation of any slide-based assays (e.g: IHC, ISH, FISH, IF, IS-PCR, SS) but at the same time reduce use of micro-reagent consumption by up to 90% thus significantly reducing the use of toxic and cancer inducing chemicals such as Formamide and Methanol.

    4. Automated Molecular Pathology Solutions - BioGenex Xmatrx staining systems contain liquid level sensor for accurate reagent dispensing and are the only staining systems in the market to allow wide reagent of dispensing volumes (10 μL to 900 μL) thus minimizing waste and reducing cost. These systems were designed to use BioGenex DeWax and Antigen Retrieval solutions for an Eco-friendly operation.

    BioGenex is committed to continued innovation in Green technologies and to providing non-toxic, environmentally friendly high-quality products for the clinical diagnostics, life science research, and drug discovery markets.

    About Us:
    BioGenex designs, develops, and commercializes advanced fully-automated molecular pathology systems for cancer diagnosis, prognosis, personalized medicine, and life science research. The recent introduction of our eFISHency integrated workflow solution for FISH laboratories and miRNA system for characterization of CUP and for undifferentiated tumors is a game changer that has no rival in the industry. Our fully-automated molecular pathology workstations are the most advanced system globally. Our customer focused approach, with premier after sales support and excellent technical service, provides the best in class customer care. Our spirit of innovation drives us to deliver cutting edge technology, years ahead of our competition, and the finest systems for life Science research and diagnostics.

    Continue reading
  • BioGenex Molecular Pathology System Aids in Finding New Treatment for Urothelial Cancer.

    Apr 21, 2016

    Urothelial Carcinoma (UCC, also known as transitional cell carcinoma) is a cancer that starts in the urothelial cells, which line the inside of the bladder and other parts of the urinary tract. According to the American Cancer Society there were over 76,000 new cases of bladder cancer diagnosed and over 15,000 deaths from advanced bladder cancer in the United States in 2014. At stage I, the 5-year survival rate is about 88% but at stage IV, the 5-year survival rate falls to 15%. Poor prognosis and ineffective therapies for patients with advanced bladder cancer make the discovery of new drugs very important for the treatment of this common disease.

    In a pioneering study published last month in Molecular Cancer Therapeutics, researchers at Agensys Inc. identified the SLITRK6 protein as a new UCC biomarker and developed a novel antibody-drug conjugate (ADC) targeting SLITRK6 for the treatment of metastatic bladder cancer. Recent advances in the antibody-drug conjugate (ADC) technology and two recently approved ADCs have brought this drug class to the forefront of drug development in oncology.

    biogenex blogExtensive immunohistochemistry (IHC) analysis using BioGenex high throughput IHC Staining system (i6000), BioGenex Super Sensitive Polymer-HRP IHC Detection System and BioGenex IHC reagents, showed that SLITRK6, a member of the SLITRK family of type I transmembrane proteins, is expressed in multiple epithelial tumors including bladder, lung and breast cancer as well as in glioblastoma. Examination of 509 formalin fixed paraffin embedded (FFPE) biopsies, representing all stages of bladder cancer showed that SLITRK6 is expressed in 90% of Urothelial Carcinomas, 100% of Metastatic bladder cancers, and 54% of other bladder cancers. The normal tissue expression profile of SLITRK6 was examined using tissue microarrays (TMAs) containing 37 different human tissues including those recommended in the FDA normal tissue panel.

    To create the antibody-drug conjugate (ADC) - a panel of fully human monoclonal antibodies specific for SLITRK6 was conjugated to the highly toxic antimitotic agent Monomethyl auristatin E (MMAE). MMAE is a drug so toxic that it can only be used as a conjugate, and works by preventing mitotic division thus suppressing tumor growth. The novel ADCs showed potent in vitro and in vivo cytotoxic activity. The most potent ADC, ASG-15ME, is currently in Phase I Clinical Trials for the treatment of metastatic urothelial cancer.

    To read the Research Manuscript Click here.

    About Us:
    BioGenex designs, develops, and commercializes advanced fully-automated molecular pathology systems for cancer diagnosis, prognosis, personalized medicine, and life science research. The recent introduction of our eFISHency integrated workflow solution for FISH laboratories and miRNA system for characterization of CUP and for undifferentiated tumors is a game changer that has no rival in the industry. Our fully-automated molecular pathology workstations are the most advanced system globally. Our customer focused approach, with premier after sales support and excellent technical service, provides the best in class customer care. Our spirit of innovation drives us to deliver cutting edge technology, years ahead of our competition, and the finest systems for life Science research and diagnostics.

    By Stephanie Erhard, April 20, 2016

    For More information on BioGenex Product and services CONTACT US or

    Continue reading
  • BioGenex products aid in micrographic surgery for invasive melanomas - a rapid 19 min IHC protocol.

    Mar 22, 2016

    Melan-A Antibody Anti-Melan-A, Clone A103

     

    The incidence of melanoma, the most deadly form of skin cancer, has doubled in the past 40 years. Globally, in 2012, melanoma occurred in 232,000 people and resulted in 55,000 deaths. In 2016, it is estimated that there will be 76,380 new cases of melanoma in the United States and 10,130 deaths from the disease. If melanoma is diagnosed and treated early, it is typically curable, but if it is not, melanoma becomes hard to treat and is often fatal.

    In a study published in the Dermatology Surgery Journal, a 19 min MART-1 immunostaining protocol using BioGenex pretreatment reagents, MART-1 Antibody and BioGenex Super Sensitive Link-Label detection system, was developed (Read full manuscript). The nineteen min immunostaining protocol in frozen sections provided information equivalent to that obtained from MART-1 stained permanent sections. The rapid turnaround time of the 19-minute protocol allows melanoma in situ to be treated using Mohs surgery within a matter of hours as opposed to days or weeks. This protocol allows increasing the number of layers that can be taken in a single day and processed using immunohistochemistry. This increase in efficiency ultimately improves the experience for the patient.

    In a new study publish in the Journal of the American Academy of Dermatology, researchers have now proven that combining Mohs surgery with MART-1 immunostaining is a very effective strategy achieving a very low recurrence rates for in situ and invasive melanomas. To read the full study please check the link.

    Mohs surgery is a precise surgical technique used to treat skin cancer. During Mohs surgery, thin layers of cancer-containing skin are progressively removed and examined until only cancer-free tissue remains. It can be difficult to identify melanocytes and to distinguish chronic sun-damaged skin from melanoma using hematoxylin and eosin (H&E)-stained frozen sections. This difficulty led to the use of MART-1 immunostaining. MART-1 (also called melan-A) is a protein antigen that is specifically found on the surface of normal melanocytes in the skin and in melanoma. MART-1 staining using permanent sections can take days, thus reducing the efficiency and cost-effectiveness of this procedure.

    The 19-min MART-1 immunostaining protocol used BioGenex Citra Buffer (HK080-9K), BioGenex Super Sensitive MultiLink (HK340-9K) and BioGenex Super Sensitive Label (HK330-9K). Mart-1 (Melan-A) Antibody for manual or automation use and positive control tissue slides are available from BioGenex as follows: AM361-5M (6 ml, RTU), MU361-UC (1 ml Conc.), MU361-5UC (0.5 ml, Conc.), AM361-10M (i6000, 10 ml, RTU), AX361-YCD (Xmatrx, 16 ml, RTU), FG-361M (5 tissue slides/Manual use), FB-361M (5 tissue slides/Xmatrx).
    Click on Antibody Page to find more.

    About Us:
    BioGenex designs, develops, and commercializes advanced fully-automated molecular pathology systems for cancer diagnosis, prognosis, personalized medicine, and life science research. The recent introduction of our eFISHency integrated workflow solution for FISH laboratories and miRNA system for characterization of CUP and for undifferentiated tumors is a game changer that has no rival in the industry. Our fully-automated molecular pathology workstations are the most advanced system globally. Our customer focused approach, with premier after sales support and excellent technical service, provides the best in class customer care. Our spirit of innovation drives us to deliver cutting edge technology, years ahead of our competition, and the finest systems for life Science research and diagnostics.

    For More information on BioGenex Product and services CONTACT US or

    Continue reading
  • BioGenex Scientists demonstrate expression of miRNA miR-17, miR-125b and miR-205 in Prostate Cancer and Benign Prostate Hyperplasia - Potentially a new diagnostic and prognostic tool.

    Mar 3, 2016

    V11-1999x390-Cave-2
    Prostate Cancer is the most frequently diagnosed form of male cancer in the USA. It is estimated that 233,000 new cases and 29,480 deaths may occur due to prostate cancer this year in the USA. Currently available diagnostic methods do not have major impact on disease out-come, highlighting the urgent need for new approaches for diagnosis and prognosis.
    The discovery of micro-RNAs (miRNAs) have enhanced our understanding of cancer biology. miRNAs are small, non-coding RNAs that regulate gene expression and play important role in Carcinogenesis and metastasis. In a recent study researchers at BioGenex profiled expression of miRNAs in different grades of prostate cancer using a novel, high-throughput, automated, in situ hybridization (ISH) technique. The finding demonstrated deregulation of miR-17 and miR-125b in high-grade prostate cancer and an increase in miR-205 expression in benign prostate hyperplasia. These results show that miRNA-ISH can be used for better diagnosis, staging and prognosis of the cancer and may be developed as tool for routine application to improve disease-outcome.
    The study was conducted using BioGenex Xmatrx Infinity automated staining platform and miRNA ISH protocols, BioGenex miRNA probes and BioGenex miRNA-ISH detection system. This Research was showcased in 2015 USCAP Annual meeting.
    For more details click here

    About Us:
    BioGenex designs, develops, and commercializes advanced fully-automated molecular pathology systems for cancer diagnosis, prognosis, personalized medicine, and life science research. The recent introduction of our eFISHency integrated workflow solution for FISH laboratories and miRNA system for characterization of CUP and for undifferentiated tumors is a game changer that has no rival in the industry. Our fully-automated molecular pathology workstations are the most advanced system globally. Our customer focused approach, with premier after sales support and excellent technical service, provides the best in class customer care. Our spirit of innovation drives us to deliver cutting edge technology, years ahead of our competition, and the finest systems for life Science research and diagnostics.

    For More information on BioGenex Product and services CONTACT US or

    Continue reading
  • BioGenex Scientists aid in unraveling the role of miRNA in Gastric Cancer proliferation and invasion.

    Feb 24, 2016

    Biogenex Blog miRNA "Inverse expression of miR-15a miRNA and Bmi-1 protein levels via in situ hybridization analysis of miR-15a (right panel) and Bmi-1 expression quantified by IHC analysis (left panel) in gastric tumor tissues."

    Advancement in the understanding of Gastric Cancer was achieved in a study published last week at the Oncotarget Journal by investigators from BioGenex, the Stony Brooks University in NY and Soochow University in China. The study investigated the contribution of MicroRNAs (miRNAs) to Gastric Cancer growth and metastasis. Gastric cancer is the fifth most common malignancy and the third leading cause of cancer-related deaths. Despite the treatment progress and research efforts in gastric cancer, the outcome of patients with stage IV disease remains disappointing, with a 5-year overall survival rate of 4%.
    The discovery of miRNAs has been one of the defining developments in cancer biology over the past decade. miRNAs are small, non-coding RNAs that regulate gene expression and have fundamental roles in Cancer growth and metastasis. In this study, researchers systematically investigated the roles of miRNA on a gene named Bmi-1, which is highly expressed in many tumors, including gastric cancer. The study found that miR-15a regulates the protein expression levels of Bmi-1 in gastric cancer. High levels of Bmi-1 in gastric cancer patients were significantly associated with better overall survival. The favorable outcome of gastric cancer patients with high levels of Bmi-1 may be due to the fact that these gastric tumor cells are highly sensitive to chemotherapy. Another possibility is that high levels of Bmi-1 are crucial in blocking metastatic process of advance stage gastric tumor in vivo.

    “We are truly excited about these findings. The phenotypic correlation found in this study using 352 gastric cancer patients is very promising and may be used in the near future to develop diagnostic and prognostic tests for gastric cancer so we can make a significant impact on patient’s lives “ says Dr. Krish Kalra, BioGenex CEO. BioGenex is leading the miRNA revolution with the most advanced miRNA solutions and the broadest portfolio of miRNA In Situ Hybridization (ISH) probes (>200), ISH detection system and affordable automation platforms for clinical research and tumor analysis.

    Click here to read the Research Manuscript

    About Us:

    BioGenex designs, develops, and commercializes advanced fully-automated molecular pathology systems for cancer diagnosis, prognosis, personalized medicine, and life science research. The recent introduction of our eFISHency integrated workflow solution for FISH laboratories and miRNA system for characterization of CUP and for undifferentiated tumors is a game changer that has no rival in the industry. Our fully-automated molecular pathology workstations are the most advanced system globally. Our customer focused approach, with premier after sales support and excellent technical service, provides the best in class customer care. Our spirit of innovation drives us to deliver cutting edge technology, years ahead of our competition, and the finest systems for life Science research and diagnostics.

    Continue reading
  • BioGenex leads the way in bringing cutting-edge diagnostic medicine to Myanmar.

    Feb 22, 2016

    BioGenex blog Dr. Hein M Htet, (MD) managing Director at HMM Co Ltd, with BioGenex technician Shanshan Chen and the Xmatrx Elite during her visit to BioGenex headquarters in Fremont, CA

    Over the last fifty years, Myanmar’s healthcare system was suffering from sever neglect and was ranked at the bottom of the list of 190 countries with respect to overall health system performance. The economic and political reforms in recent years have brought an opportunity for change. BioGenex is now taking the lead in bringing cutting-edge diagnostic medicine to Myanmar hospitals and clinical laboratories. Together with our partner, Dr. Hein M Htet, the managing Director at HMM Co Ltd, and a well known Senior Pathologist in Myanmar, we have installed the first advanced pathology automation systems, the Xmatrx® Elite and the i6000® Diagnostics, at some of Myanmar largest medical centers including Zabuthiri Specialists Hospital in Nay Pyi Taw, and TOP TEAM LAB in Mandalay. Xmatrx ELITE – is the world’s first and only fully-automated high throughput staining system that enables IHC, ISH, FISH, multiplexing and special stains on a single platform. The Xmatrx and i6000 systems can aid in the diagnosis of various cancers, vascular diseases, neurological abnormalities, genetic aberrations and many other conditions. This automated systems maximizes testing capacity, minimizes hands-on time, reduces errors and produces consistent and accurate results. To ensure correct and efficient operation, BioGenex provides Myanmar’s hospital staff, with technical and scientific training, technical support and all reagents and ancillaries for the operation of these automated staining systems. In February, Dr. Min came to BioGenex headquarter in Fremont California, in order to plan a new setup for an IHC laboratory, discuss future research collaborations and prepare for the installation of additional automation units in Myanmar hospitals. “We believe all people around the world have the right to the highest attainable standard of health and that companies have a social responsibility to spread medical technology and innovation and make them accessible to everyone” said Dr. Kalra, BioGenex CEO. BioGenex engagement in Myanmar underlies our commitment to providing top notch automated systems and reagents for pathology labs around the world.

    About Us:
    BioGenex designs, develops, and commercializes advanced fully-automated molecular pathology systems for cancer diagnosis, prognosis, personalized medicine, and life science research. The recent introduction of our eFISHency integrated workflow solution for FISH laboratories and miRNA system for characterization of CUP and for undifferentiated tumors is a game changer that has no rival in the industry. Our fully-automated molecular pathology workstations are the most advanced system globally. Our customer focused approach, with premier after sales support and excellent technical service, provides the best in class customer care. Our spirit of innovation drives us to deliver cutting edge technology, years ahead of our competition, and the finest systems for life Science research and diagnostics.

    Continue reading